Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akari Therapeutics plc (AKTX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and proxy materials related to its oncology ADC platform. These documents are a primary source for understanding how Akari describes its PH1 spliceosome-modulating payload, lead ADC candidate AKTX-101, and broader corporate strategy.
Through Forms 8-K, Akari reports material events such as equity financings, warrant issuances, note offerings and exchanges, manufacturing partnerships, and leadership changes. Recent 8-K filings detail registered direct offerings and concurrent private placements, the terms of Series E, Series F, and Series G warrants, exchanges of unsecured promissory notes into equity-linked securities, and the company’s plans to use net proceeds for research and development, working capital, and general corporate purposes. Other 8-Ks describe Nasdaq minimum bid price deficiency notices and the company’s responses.
Akari’s registration statements, including shelf registrations and resale S-1 filings, outline the structure of its American Depositary Shares, the number of ordinary shares underlying various warrant series, and risk factor discussions related to its status as a development-stage oncology company without approved products or product revenue. These filings also summarize the company’s focus on developing ADCs with novel payloads and the role of its ADC discovery platform.
Proxy statements (DEF 14A) provide detail on shareholder meetings, resolutions related to share sub-division, warrant exercisability, authority to allot shares, and adoption of new articles of association. They also describe voting procedures for ordinary shareholders and ADS holders.
On Stock Titan, Akari’s SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight key terms, capital structure changes, and regulatory milestones. Users can quickly scan 10-K or 20-F style risk discussions (when available), 10-Q or 6-K interim updates, and Form 4 insider transaction reports, then drill into the full text for deeper analysis of how financing, governance, and listing matters intersect with the company’s PH1-based ADC development plans.
Akari Therapeutics (AKTX) calls a Dec 15, 2025 general meeting to seek approval for the exercisability of warrants to purchase an aggregate 6,375,000 ADSs under Nasdaq Listing Rule 5635(d), and to implement a capital reorganization.
Resolution 1 covers Series E and F Investor Warrants at an $0.98 exercise price and Placement Agent Warrants at $1.00, with potential gross cash proceeds of approximately $6.25 million if fully exercised for cash. Warrants include a 4.99% (or 9.99%) beneficial ownership cap.
Resolutions 2–6 propose: sub‑division reducing ordinary share nominal value from $0.0001 to $0.000000005 and creation of 1,429,517,750,998,477 Deferred Shares; director authority to allot up to $3,000 nominal (through June 30, 2030); approval to buy back and cancel all Deferred Shares for $0.01; disapplication of pre‑emption rights (through June 30, 2030); and adoption of New Articles. The board unanimously recommends voting FOR all proposals.
Record time for ordinary shareholders is 6:30 p.m. London on Dec 11, 2025; ADS voting instructions are due by Dec 4, 2025.
Akari Therapeutics (AKTX) reported an insider equity grant by its Interim CFO. On 11/01/2025, the officer acquired 32,000 and 26,619 American Depositary Shares (ADS) at $0.75 per ADS. The filing lists post‑transaction beneficial ownership of 32,000 and 26,619 ADS, held directly.
These ADSs represent restricted stock units (RSUs) that vest on January 1, 2026 and February 15, 2026. Each ADS represents 2,000 ordinary shares.
Akari Therapeutics (AKTX) disclosed a Form 4 showing its Interim CFO acquired 6,277 American Depositary Shares on October 22, 2025, reported as code A at $0.74 per ADS. Following the transaction, 6,277 ADS are beneficially owned with direct ownership.
The filing notes these ADSs represent restricted stock units (RSUs) that vest on October 31, 2025. Each ADS represents 2,000 Ordinary Shares of the company.
Akari Therapeutics (AKTX) reported an initial beneficial ownership filing on Form 3 for an officer serving as Interim CFO. The filing indicates no securities are beneficially owned, as stated in the remarks. The event date is 10/22/2025, and the form was filed by one reporting person. A Power of Attorney (Exhibit 24) is referenced for the signature authorization.
Akari Therapeutics (AKTX) appointed Kameel Farag as interim CFO, effective October 22, 2025, succeeding prior CFO Torsten Hombeck. Farag brings senior finance experience from Aspen Neuroscience, Ionis, and Amgen, and serves on the Biovie board.
The company entered a Consulting Agreement with Farag and KDF Ventures LLC. Through the end of 2025, compensation is $18,000 per month in cash plus $12,000 in RSUs, vesting monthly. From January 1, 2026 to February 15, 2026, fees increase to $27,000 cash plus $13,000 in RSUs, vesting monthly. The agreement runs to February 16, 2026 and can be extended month‑to‑month at the company’s discretion. In connection with certain capital raises, KDF Ventures may receive additional cash and RSU compensation based on a percentage of total gross proceeds, subject to maximum limits and timing conditions.
Akari Therapeutics (AKTX) launched a primary registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for gross proceeds of $2.5 million. The deal is on a best efforts basis via Ladenburg Thalmann, with no minimum. The company estimates net proceeds of approximately $1.8 million after placement agent fees and offering expenses, and expects delivery around October 16, 2025, subject to customary closing conditions.
In a concurrent private placement, Akari is issuing 3,125,000 Series E warrants and 3,125,000 Series F warrants, each exercisable for one ADS at $0.98 per ADS, beginning on the Shareholder Approval Date. These warrants and the ADSs issuable upon exercise are not registered here. The company plans to file a resale registration statement within 30 days after closing. Akari intends to use net proceeds for working capital, general corporate purposes, and continued R&D, including generating differentiated data on its novel ADC payload. The company states that, together with existing cash, funds are expected to meet capital needs into December 2025. The filing notes expected immediate and substantial dilution of approximately $1.44 per ADS to new purchasers.
Akari Therapeutics entered a registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for expected $2.5 million in aggregate gross proceeds, subject to customary closing conditions. The ADS sale is a takedown from Akari’s effective Form F-3 shelf.
Concurrently, the company issued Series E and Series F warrants in a private placement, each exercisable for up to 3,125,000 ADSs at an exercise price of $0.98 per ADS. Both series become exercisable on the effective date of shareholder approval; Series E carries a five-year term and Series F a thirty‑month term. Akari will file a resale registration for the warrant shares within 30 days of closing and will call a shareholder meeting within 60 days to seek approval, then every 40 days until obtained or the warrants expire.
Ladenburg Thalmann is placement agent, entitled to a 7.2% fee, 0.5% management fee, up to $75,000 expense allowance, and Placement Agent Warrants to purchase 125,000 ADSs at $1.00 per ADS (five‑year term). The purchase agreement includes a 30‑day issuance/registration standstill and a one‑year prohibition on variable rate transactions, in each case with customary exceptions.
Akari Therapeutics (AKTX) furnished an 8-K announcing a $2.5 million registered direct offering. The company disclosed, under Item 7.01 (Regulation FD), that it issued a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.” The press release is included as an exhibit and the furnished information is not deemed filed under the Exchange Act.
Akari’s American Depositary Shares, each representing 2,000 ordinary shares, trade on Nasdaq under the symbol AKTX. The filing lists the date of the earliest event as October 15, 2025.
Akari Therapeutics, Plc reports that it has completed its previously disclosed August 2025 unsecured promissory notes financing. The company had agreed to sell notes with a 20% original issue discount for an aggregate purchase price of $3 million, resulting in a total principal amount of approximately $3.8 million.
On September 26, 2025, Akari closed the final tranche of this private placement, issuing $312,500 in aggregate principal amount of August 2025 Notes for a purchase price of $250,000. After this closing, the full approximate $3.8 million principal amount of August 2025 Notes has been issued to investors.
Akari Therapeutics reported several financing changes and new preclinical data. The company amended its April 2023 convertible notes and warrants assumed in its merger with Peak Bio. The maturity of $0.7 million principal of notes was extended to August 31, 2026 and the conversion price was reduced to $0.81 per ADS. The related warrants were extended to August 31, 2030, with 342,420 ADSs now issuable at an exercise price of $0.81 per ADS, and holders will receive about $81,700 of accrued interest.
Akari also closed a second tranche of its August 2025 notes offering, issuing $625,000 principal for $500,000 in proceeds, bringing total August 2025 notes issued to $3.5 million principal. In connection with this, Series A warrants to purchase 4,891,272 ADSs had their expiration extended to April 25, 2030. Separately, Akari described preclinical results for its PH1 antibody-drug conjugate payload showing AR-V7 suppression and combination activity with existing androgen receptor pathway inhibitors in prostate cancer models.